Non-invasive prenatal screening solutions(NIPT)
Solution Introduction:
Non-Invasive Prenatal Testing (NIPT), also known as non-invasive prenatal screening (NIPS) or cell-free fetal DNA (cffDNA) based screening technology in maternal plasma, It is a novel prenatal screening method that assesses whether the fetus has chromosomal abnormalities by analyzing the DNA fragments from the placenta in the maternal peripheral blood. It can accurately determine whether the fetus has Down syndrome (trisomy 21), Edward's syndrome (trisomy 18), and Patdow's syndrome (trisomy 13). Due to its safety, accuracy, early and rapid advantages, more than one million pregnant women in the world have received non-invasive prenatal fetal DNA testing, and experts at home and abroad have recognized that prenatal testing has entered the "NIPT era".
Solution Feature：
（1）Non-invasive and with no risk of miscarriage. Only 10mL of the pregnant woman's peripheral blood needs to be drawn for testing. Replace the traditional Down's syndrome screening (serology +NT) and reduce unnecessary amniocentesis.
（2）Suitable for the early stage of pregnancy
The test can be conducted between 12 and 22 weeks of pregnancy.
（3）High Sensitivity
The detection rate is over 99%.
Solution Process：
